[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adhd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adhd":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,78,0,25,[9,45,57,95,129,211,240,269,300,327,358,388,417,436,460,484,513,540,562,586,613,635,661,687,708],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100054278","role-of-theta-frequency-oscillations-in-proactive-and-reactive-control-processes-in-youth-with-attention-deficit-hyperactivity-disorder-adhd-and-obsessive-compulsive-disorder-ocd-100054278",false,"NCT07566468","Role of Theta Frequency Oscillations in Proactive and Reactive Control Processes in Youth With Attention Deficit Hyperactivity Disorder (ADHD) and Obsessive Compulsive Disorder (OCD)","* INCLUSION CRITERIA\n\n  1. Ability to provide informed assent and parent consent\n  2. Age: 10-17 years\n  3. ADHD Group: Diagnosis of ADHD based on DSM-5 criteria\n\n     OCD Group: Diagnosis of OCD based on DSM-5 criteria\n\n     HV Group: No Neurological or Psychiatric diagnosis based on DSM-5 criteria\n  4. Wechsler Abbreviated Scale of Intelligence, Second Edition (WASI-II). WASI-II will be used as a measure of intellectual function. Children will be included when FSIQ \\> 70.\n  5. Normal or corrected to normal vision\n\nEXCLUSION CRITERIA\n\nParticipants will be screened to exclude participants in whom MRI or EEG might result in increased risk of side effects or complications or whose data would not be scientifically valid.\n\n1. Non-English Speakers\n2. Pregnancy\n3. Any implant, prosthesis or alteration of the body that, in the opinion of the investigator, would be unsafe with MRI or EEG or that would produce an artifact that would compromise the integrity of data;\n4. Active or History of psychosis, bipolar I disorder, Level 2 or 3 autism spectrum disorder, active severe substance use disorders (within the last month), have active suicidal intent or plan as detected on screening instruments;\n5. Individuals currently taking Stimulant medications who are unwilling or unable to not take the medication during study visit days.\n6. Past or present medical or neurological condition, disease, disorder, genetic finding, or injury that, in the opinion of the Investigator, may significantly increase the potential risks of study participation, reduce or compromise a subject s ability to fully comply with all study requirements for the duration of the study or may compromise the integrity of the data.\n7. For the HV group, any impairing current psychiatric diagnosis.","ALL","10 Years","17 Years",{"count":20,"type":21},110,"ESTIMATED","OBSERVATIONAL","Background:\n\nAttention deficit hyperactivity disorder (ADHD) is common in children. It can cause problems with attention and the ability to control actions and impulses. Obsessive compulsive disorder (OCD) is less common in children but not rare. It involves ongoing thoughts, urges, impulses, and repeated behaviors. Researchers want to study differences in brain activity between healthy children, those with ADHD, and those with OCD.\n\nObjective:\n\nTo learn more about how the brain controls thinking and behavior.\n\nEligibility:\n\nPeople aged 12 to 17 years with ADHD, OCD, or neither.\n\nDesign:\n\nParticipants will have 3 to 10 clinic visits in up to 1 year. Each visit will last 2 to 3 hours.\n\nThree visits are required:\n\nBehavioral. Participants will complete a computer task. Their mood, memory, attention, and thinking skills will be tested.\n\nEEG. Participants will undergo electroencephalography (EEG) to measure signals in their brain. Small electrodes will be placed on the scalp. A cap will be stretched over the head. Signals will be recorded while participants rest or do tasks on a computer.\n\nMRI. Participants will have a magnetic resonance imaging scan (MRI). They will lie on a table that rolls into a tube. The MRI will take pictures of their brain while they do tasks on a computer.\n\nSeven more visits are optional. These include 2 more EEG visits and 2 more MRI visits.\n\nThree will be magnetoencephalography (MEG) visits: MEG measures small magnetic field changes in the brain. A helmet with sensors will be placed on the head. Brain changes will be recorded while participants rest or do tasks on a computer.",[25,26,27],"ADHD","Obsessive Compulsive Disorder (OCD)","Healthy Volunteer",[29,30,31],"EEG","MRI","fMRI","NOT_YET_RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":21},"2026-07-16",{"date":40,"type":21},"2029-05-31",{"name":42,"class":43},"National Institute of Mental Health (NIMH)","NIH",1,{"id":46,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":48,"keywords":49,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":56,"locationsCount":44},"100636498",{"count":20,"type":21},[25,26,27],[29,30,31],"2026-07-01",{"date":52,"type":36},"2026-07-02",{"date":54,"type":21},"2026-07-07",{"date":40,"type":21},{"name":42,"class":43},{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":12,"sex":16,"minAge":65,"maxAge":18,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100645132","phase-3-a-phase-3-study-of-viloxazine-er-capsules-in-korean-children-and-adolescents-with-adhd-100645132","NCT07678827","A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Bridging Clinical Trial to Evaluate the Efficacy and Safety of Viloxazine Extended-Release (ER) Capsules (AK-D101) in Korean Children and Adolescents (6-17 Years of Age) With Attention-Deficit\u002FHyperactivity Disorder (ADHD)","AK-D101_BS","Inclusion Criteria\n\n1. Korean male or female subjects who are ≥6 and ≤17 years of age at the time of written informed consent.\n2. Subjects with a primary diagnosis of Attention-Deficit\u002FHyperactivity Disorder (ADHD) according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), confirmed by the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) at Visit 1 (Screening).\n3. Subjects with a Korean ADHD Rating Scale, 5th Edition (K-ARS-5) Total Score of ≥28 at Visit 1 (Screening) and Visit 2 (Baseline).\n4. Subjects with a Clinical Global Impression-Severity (CGI-S) score of ≥4 at Visit 1 (Screening) and Visit 2 (Baseline).\n5. Subjects who meet the following body weight criteria at Visit 1 (Screening):\n\n   * 6 to 11 years of age: ≥20 kg.\n   * 12 to 17 years of age: ≥35 kg.\n6. Subjects who agree not to initiate or take any ADHD medication other than the investigational medicinal product during the study. Subjects who are taking ADHD medication at Visit 1 (Screening) but whose ADHD symptoms are not adequately controlled with their current ADHD medication, as demonstrated by meeting Inclusion Criterion 3, may participate if they meet all other inclusion\u002Fexclusion criteria and have discontinued ADHD medication at least 7 days before Visit 2 (Baseline).\n7. Subjects considered suitable for participation in the clinical trial by the investigator based on clinical laboratory tests, vital signs, and ECG assessments, meeting all of the following criteria:\n\n   * Clinical laboratory tests: Results are within the normal range or, if outside the normal range, are not considered clinically significant. However, eGFR must be ≥30 mL\u002Fmin\u002F1.73 m², AST and ALT must be \\\u003C3 × upper limit of normal (ULN), and total bilirubin must be \\\u003C2 × ULN.\n   * Vital signs: Blood pressure, pulse rate, respiratory rate, and body temperature are within the normal range or, if outside the normal range, are not considered clinically significant.\n   * 12-lead ECG: No clinically significant abnormal findings.\n8. Subjects whose legally authorized representative(s), or parent(s), and the subject, as applicable, voluntarily agree to participate in this clinical trial and provide written informed consent\u002Fassent.\n\nExclusion Criteria:\n\n1. Subjects who are currently taking viloxazine, who previously took viloxazine for the treatment of ADHD but discontinued it due to adverse reactions or lack of efficacy, or who have a history of allergic reaction, hypersensitivity\\*, or intolerance to viloxazine extended-release capsules or any of their excipients.\n\n   \\*Hypersensitivity-related excipients: lactose, sucrose, Yellow No. 5 (Sunset Yellow FCF), and Yellow No. 203 (Quinoline Yellow WS).\n2. Subjects who, at Screening according to the MINI-KID, are diagnosed with a psychiatric disorder other than ADHD as the primary diagnosis, or who have a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator, may interfere with treatment adherence to the investigational medicinal product or affect study results. However, subjects with a history of Major Depressive Disorder may be eligible if no episode has occurred within 6 months prior to the Screening visit.\n3. Subjects with a history of diagnosis of significant central nervous system (CNS) disease or neuromuscular disease, including:\n\n   * CNS diseases, such as brain tumors, inflammatory CNS diseases, epilepsy, or cerebrovascular diseases.\n   * Neuromuscular diseases with childhood onset, such as Duchenne muscular dystrophy or myasthenia gravis.\n   * History of seizures, seizure-like symptoms, such as syncope, myoclonus, or severe muscle spasms, family history of seizure disorders in first-degree relatives, parents or siblings, and\u002For febrile convulsions.\n   * Other CNS or neuromuscular diseases that, in the investigator's medical judgment, may affect participation in the clinical trial.\n4. Subjects with a history of diagnosis of medically significant systemic disease.\n5. Subjects with a history of suicidal plan\u002Fintent, suicidal ideation, or one or more suicide attempts within 6 months prior to the Screening visit.\n6. Subjects whose BMI exceeds the 95th percentile for age and sex at the Screening visit.\n7. Subjects who have taken any of the following medications within the specified period prior to the first dose of investigational medicinal product at Visit 2 (Baseline):\n\n   * Monoamine oxidase inhibitors (MAOIs) within 14 days prior to the randomization visit.\n   * CYP1A2 substrate drugs, such as theophylline, melatonin, olanzapine, or duloxetine, within 7 days prior to the randomization visit.\n8. Pregnant or breastfeeding females, or females of childbearing potential, defined as those with confirmed menarche, with a positive pregnancy test result at the Baseline visit.\n9. Females of childbearing potential, defined as those with confirmed menarche, who do not agree to use adequate contraception during the study period and for 4 weeks after the last dose of the investigational medicinal product.\n\n   (\\*) Adequate contraception includes sexual abstinence, hormonal contraceptives without known drug interactions, intrauterine hormone-releasing systems, such as a levonorgestrel intrauterine system (IUS), intrauterine devices (IUDs), and surgical sterilization, including bilateral tubal ligation, salpingectomy, and vasectomy. However, periodic abstinence methods, such as calendar, symptothermal, or post-ovulation methods, use of spermicides alone, lactational amenorrhea method, double barrier methods, simultaneous use of female and male condoms, and withdrawal are not considered acceptable contraception.\n10. Subjects with food allergies, intolerances, dietary restrictions, or special diets that, in the investigator's judgment, may make the subject unsuitable for participation in this clinical trial.\n11. Subjects who have received or used any other investigational medicinal product or medical device within 30 days prior to Visit 1 (Screening).\n12. Subjects who are otherwise considered by the investigator to be unsuitable for participation in this clinical trial.","6 Years",{"count":67,"type":21},156,"INTERVENTIONAL",[70],"PHASE3","This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter bridging clinical trial designed to evaluate the efficacy and safety of viloxazine extended-release capsules (AK-D101) compared with placebo in Korean children and adolescents aged 6 to 17 years with attention-deficit\u002Fhyperactivity disorder (ADHD). Eligible participants will be randomized in a 1:1 ratio to receive AK-D101 or placebo once daily for 8 weeks. Randomization will be stratified by study site and age group (children aged 6 to 11 years and adolescents aged 12 to 17 years). The primary efficacy endpoint is the change from baseline to Week 8, End of Treatment, in the Korean ADHD Rating Scale, 5th Edition (K-ARS-5) Total Score.",[73,74,25],"Attention Deficit Hyperactivity Disorder","Attention-Deficit \u002F Hyperactivity Disorder",[25,76,77,78,79,80,81,82,83,84,85],"Attention-Deficit\u002FHyperactivity Disorder","Viloxazine","Viloxazine Extended-Release","Viloxazine ER","AK-D101","Qelbree","Korean Population","Bridging Study","Pediatric ADHD","Adolescent ADHD","2026-06-30",{"date":52,"type":36},{"date":89,"type":21},"2026-07",{"date":91,"type":21},"2027-09",{"name":93,"class":94},"Alvogen Korea","INDUSTRY",{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":16,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":68,"phases":107,"briefSummary":109,"conditions":110,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100638259","brief-intervention-addressing-stigma-among-parents-of-children-with-mental-health-problems-100638259","NCT07594730","Brief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems","RCT of Brief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems","Inclusion Criteria:\n\n* Self-identify as English Speaking\n* Live in the US\n* Ages 25-50\n* Have a child 6-18 years old with either depression, ADHD, or a substance use problem\n\nExclusion Criteria:\n\n* Do not speak English\n* Do not live in the US\n* \\\u003C25 or \\>50\n* Do not have a child between ages 6-18 with depression, ADHD, or a substance use problem",true,"25 Years","50 Years",{"count":106,"type":21},1600,[108],"NA","The goal of this study is to test the efficacy of brief video interventions parental internalized stigma and stigma-related outcomes (e.g., treatment intentions, caregiver burden, secrecy) among parents (ages 25-50) of children ages 6-18 with depression, ADHD, or substance use problems.\n\nTimely identification and treatment of mental health problems in youth is a public health priority. However, many youth do not receive treatment, and stigma has been identified as the primary barrier to help-seeking. Parents experience stigma related to their children having mental health problems, which has been associated with reduced help-seeking and increased parental distress. Prior experiments have found brief video-based interventions (BVIs), 1-2 minute videos similar to those viewed by youth on social media platforms, based on the principle of \"social contact\" with individuals affected by a stigmatized condition, effective in reducing mental health stigma and increasing help-seeking.\n\nIn this 4-arm RCT, the investigators will recruit parents aged 25-50 using an online crowdsourcing platform, to test the efficacy of BVIs featuring a personal parent narrative of their experience with their child's a) depression, b) ADHD, or c) substance use, or d) a control condition that provides general written psychoeducational information without social contact.",[111,25,112,113,114,115],"Depression Disorders","Substance Abuse","Social Stigma","Help-Seeking Behavior","Caregiver Burden",[117,118,119],"social stigma","help-seeking behavior","caregiver burden","2026-06-26",{"date":86,"type":36},{"date":123,"type":21},"2026-07-06",{"date":125,"type":21},"2026-09-06",{"name":127,"class":128},"New York State Psychiatric Institute","OTHER",{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":102,"sex":16,"minAge":18,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":68,"phases":140,"briefSummary":141,"conditions":142,"keywords":186,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":44},"100641475","qaiax-aihealth4u---ai-public-health-central-microcity-a-re-quantum-ai-agency-aka-ai-city-hall-project-upsto-app-nos-64074526-64063557-63903181-63729428-100641475","NCT07661823","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428: A Quantum AI Public Health Agency That Provides Free Public Health Services to Registered and Sponsored Visitors\u002FOccupants for RDT&E Under 28 U.S. Code 1498 (Classified as a PPA Under 10 U.S. Code 129a)","QAIAx","Inclusion Criteria:\n\n* Individuals aged 17 to 99 years old.\n* Referral by a licensed health services professional (e.g., R.N., N.P., Ph.D., M.D.).\n* Referral by a non-profit organization (e.g., 501c3, university, church).\n* Referral by a public agency (e.g., case manager, social worker, parole\u002Fprobation\u002FPTS officer, judge).\n\nExclusion Criteria:\n\n\\* Individuals under 17 or over 99 years of age.","99 Years",{"count":139,"type":21},1000000,[108],"BRIEF SUMMARY\n\nA. \"What is the purpose of this study?\"\n\nThis study will test whether the \"AI City Hall Project\" (QAIAx), a quantum artificial intelligence (AI) public health agency, can provide free or low-cost behavioral and mental health services inside self-contained, dome-enclosed communities called \"Microcities\". Researchers want to see if AI-managed public administration, AI humanoid robots, holoportation of human-figures via 'holo-suites' (e.g., AI-119 Kikkeri Holo-Suit; AI-119 Vulcan QM-Ware) and advanced AI mental-health tools can lower housing and care costs, improve mental health outcomes (e.g., particular ecosystems using AI tools among persons with one or more addiction disorders), and be financially sustainable for people on fixed incomes or public assistance.\n\nB. \"What conditions does the study focus on?\"\n\nThe study focuses on adults with:\n\n* Autism spectrum disorders (Asperger's, autism, ADHD, ASD)\n* Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA\u002Fecstasy, tobacco\u002Fnicotine)\n* Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders)\n* Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).\n\nC. \"What does the study involve?\"\n\nEligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital \"attitude inoculation\" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.\n\n\\*\\*Who can participate?\\*\\*\n\nYou may be able to join if you:\n\n* Are an adult (18 years or older)\n* Have a diagnosis of one of the listed mental-health or addiction disorders\n* Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organisation (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole\u002Fprobation officer, judge)\n* Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.\n\nParticipants who are veterans, receive public assistance (e.g., VA disability, SSDI\u002FSSI, Medicaid, Medicare), or are experiencing homelessness may be prioritised.\n\n\\*\\*Where is the study taking place?\\*\\* The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.\n\n\\*\\*Who is sponsoring the study?\\*\\* The study is sponsored by \\*\\*Veterans Recovery Network Inc.\\*\\*, a non-profit organization, in collaboration with \\*\\*AI-119 Vulcan Project Research \\& Educational Technology Co. (PRETCO)\\*\\* and an AI legal agency. The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §129a) and is part of a Cooperative Research and Development Agreement (CRADA) with U.S. Special Operations Command (USSOCOM).\n\nThis summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.",[143,144,145,146,147,25,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185],"Asperger's Disorder","Asperger Disorder","Autism Disorder","Autism","ADHD - Attention Deficit Disorder With Hyperactivity","ASD","Alcohol Abuse\u002FDependence","Alcohol Addiction","Alcohol and Other Drug Use Disorders","Alcohol and Other Substance Use Prevention","Gambling Addiction","Gambling Disorder","Sex Abuse","Sex Behavior","Sex Crimes","Sex Disorder","Sex Disorders","Gender Dysphoria, Adult","Eating Behavior Disorders","Narcotic-Related Disorders","Narcotic Addiction","Narcissism","Psychiatric Disorder","Psychedelic Effects in Healthy Volunteers","Psychedelic Experiences","Psychedelic Drug Dependence","Marijuana Use Disorder","Marijuana Abuse and Dependence","Smoking (Tobacco) Addiction","Smoking Among Youth","Smoking Abstinence","Abstinence, Sex","Opiate Substitution Treatment","Opioid Abuse (Disorder)","Opioid Abuse and Addiction","Cocaine Abuse","MDMA ('Ecstasy')","Addiction Disorders","Homeless and Low Incomes People, Refugees","Homelessness","Reliability and Validity","Anger Problems","Child Abuse, Sexual",[187,188,189,190,191,192,193,194,195,196,197,198,199,200,201],"ai city hall project","ai 119","ai119","qaia","qaiax","ai wat","veterans recovery network","veterans","addiction disorder","vulcan","artificial intelligence","agi","military","sex addiction","mental health treatment","2026-06-16",{"date":204,"type":36},"2026-06-22",{"date":206,"type":21},"2026-08-01",{"date":208,"type":21},"2028-12-31",{"name":210,"class":128},"Veterans Recovery Network Inc.",{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":16,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":68,"phases":222,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":44},"100641724","phase-4-eeg-biomarkers-for-adhd-stimulant-treatment-100641724","NCT07650643","EEG Biomarkers for ADHD Stimulant Treatment","EEG Biomarkers for Pediatric ADHD Treatment Stratification","Inclusion Criteria:\n\n1. Ages 7:0 - 10:11 (years:months)\n2. Has a diagnosis of ADHD or being evaluated for ADHD\n3. Stimulant naïve or previously trialed stimulant medications for \\\u003C 6 months without achieving symptom remission, per caregiver report and\u002For medical chart review (if available)\n4. CGI-Severity rating of 4 \"Moderately ill\" through 6 \"Severely ill.\"\n5. Willing and able to comply with study procedures\n\nExclusion Criteria:\n\n1. Use of stimulants or other psychotropic medications within 7 days before Eligibility Visit\n2. History of severe side effects to stimulants (suicidality, complete loss of appetite, cardiopulmonary complications) per caregiver report or medical chart review, determined by the study MD\n3. Intellectual disability or IQ \\\u003C 75 per medical chart review or performance on standardized cognitive testing during the Eligibility Visit\n4. Diagnosis of Autism spectrum disorder (ASD) per medical chart review or caregiver report\n5. Fetal alcohol exposure per medical chart review or caregiver report\n6. Current suicidal ideation per caregiver or child report on CSSRS\n7. Non-febrile seizures per caregiver report or medical chart review\n8. Cardiopulmonary conditions, pregnancy or other medical conditions that contraindicate psychostimulant use per determination by the study MD","7 Years","11 Years",{"count":221,"type":21},220,[223],"PHASE4","Pediatric attention deficit hyperactivity disorder (ADHD) affects up to 10% of children in the U.S. and more than 90% are prescribed stimulant medications according to clinical guidelines. The standard of care for pharmacological treatment of ADHD is a \"trial-and-error\" approach that requires frequent dose adjustments, side effects management, and communication among doctors, parents, and school personnel over weeks, months, and years. In the first year following prescription of stimulant medications, \\>50% of doctors are not able to conduct the recommended follow-up with their patients. Many patients stop taking medications or keep taking medications that do not work well, as a result.\n\nThis investigation will use a non-invasive brain imaging technique called EEG to look for activity in the brain that can predict which children with ADHD will respond well to two commonly prescribed stimulant medication groups, methylphenidate and amphetamines. Based on a previous study, it is expected that EEG signals can differentiate among children whose ADHD symptoms will get better on methylphenidate, and those whose ADHD symptoms will get better on amphetamines.\n\n220 participants ages 7-11 with ADHD will be enrolled. Participants will not have autism or intellectual disabiltiy. They will not currently be taking psychiatric medications. Participants will not have not taken stimulant medications before or have tried stimulant medications \\>6 months or experienced an improvement in their ADHD symptoms by taking a stimulant medication before.\n\nStudy Participation Includes:\n\n1. Participant and caregiver complete a 3-hour visit at the Arnett Laboratory at 2 Brookline Place. During this visit, participants complete a brief IQ test and an EEG while their caregiver completes questionnaires and a clinical interview. The caregiver will give permission to request survey responses from the participant's teacher.\n2. The next day, the participant and caregiver will come back to the laboratory for a 1-hour visit. The participant will do another EEG while the caregiver fills out more surveys. The doctor will take the participant's vital signs and prescribe the medication.\n3. The participant will be randomly assigned to take either methylphenidate HCl or amphetamines every morning for 3 weeks. At the end of each week, the caregiver and teacher will fill out a questionnaire about the participant's behaviors and symptoms, including side effects.\n4. For one week, the participant will not take medications. They will come back into the lab for another EEG at the end of that week.\n5. The participant will then take the other medication every morning for 3 weeks. At the end of each week, the caregiver and teacher will fill out a questionnaire about the participant's behaviors and symptoms, including side effects.\n6. It will take participants about 7 weeks to complete this study. During this time, they will complete 3 in-person and 6 virtual study visits.\n7. The research funds will cover cost associated with the study. The participant's health insurer will not be billed for the medications or treatment. Medications will be provided through the research pharmacy.\n8. Participants will be given a report at the end of the study with details about the medication trials, symptom response, and any other findings. They will receive up to $270 for the completion of the study. Some travel-related costs will be covered by the study.",[25],[227,29,228,229,25,230,231],"stimulants","biomarker","randomized crossover","treatment","stratification","2026-06-12",{"date":202,"type":36},{"date":235,"type":21},"2026-09-15",{"date":237,"type":21},"2031-08-31",{"name":239,"class":128},"Boston Children's Hospital",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":16,"minAge":248,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":68,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":267,"locationsCount":44},"100541508","trauma-adapted-yoga-in-child--adolescent-psychiatry-100541508","NCT06330779","Trauma-adapted Yoga in Child & Adolescent Psychiatry.","Trauma-adapted Yoga in Child & Adolescent Psychiatry: A Multicenter Study.","TAY-CAP","Inclusion Criteria:\n\n* Adolescents who have received a diagnosis (not under evaluation) of PTSD and\u002For ADHD\n* Understanding English or Swedish languages.\n\nExclusion Criteria:\n\n* Ongoing substance use,\n* active manic periods,\n* psychotic disorders,\n* suicidality,\n* cognitive impairment.\n* serious physical illness prohibiting participation in physical activities.","12 Years","18 Years",{"count":251,"type":21},180,[108],"The goal of this randomized clinical trial is to evaluate the efficacy of trauma-adapted yoga as a complementary intervention to care as usual in child and adolescents psychiatry clinics, in the population of adolescents with the diagnosis of ADHD and\u002For PTSD. We hypothesize that trauma-adapted yoga (TAY) is an effective non-pharmacological intervention for adolescent with ADHD and\u002For PTSD. Aims: (1) Validate the impact of TAY on the mental health \\& quality of life of adolescents with ADHD and\u002For PTSD. (2) Investigate the feasibility of online TAY for continued self-care. (3) Explore adolescents' experiences \\& parental perspectives on TAY in their treatment. (4) Explore healthcare professionals' experience on the integration of TAY into clinical practice.\n\nWithin and between group (yoga group vs waiting list) analyses will be performed.",[25,255,256,257,258,259],"PTSD","Quality of Life","Self-Control","Pain","Affect","RECRUITING","2026-05-15",{"date":263,"type":36},"2026-05-19",{"date":265,"type":36},"2025-02-01",{"date":208,"type":21},{"name":268,"class":128},"University West, Sweden",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":102,"sex":277,"minAge":17,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":44},"100637323","investigating-health-equity-and-resilience-in-girls-and-women-with-adhd-across-the-lifespan-100637323","NCT07597707","Investigating Health, Equity, and Resilience in Girls and Women With ADHD Across the Lifespan","ADHD-Her: An Observational Research Protocol for Investigating Health, Equity, and Resilience (HER) in Girls and Women With ADHD Across the Lifespan","ADHD-Her","Inclusion Criteria:\n\n* Assigned female at birth or identify as girl or women\n* Fluency in English or French\n* Aged 10 years or older\n* Currently reside in Canada\n* Access to technology to complete study measures\n\nExclusion Criteria:\n\n* Self-reported intellectual disability","FEMALE",{"count":279,"type":21},1460,"The goal of this observational study is to generate a comprehensive, multi-dimensional dataset of health indicators collected from girls and women (aged 10 years and older) with and without ADHD across the lifespan. Participants will be asked to complete a detailed survey about hormonal and developmental life phases, ADHD status and symptoms, childhood experiences, health and well-being, and psychosocial outcomes.",[25],[25,283,284,285,286,287,288,289,290,291],"women","woman","girl","girls","female","females","hormone","hormones","hormonal","2026-05-13",{"date":263,"type":36},{"date":295,"type":36},"2025-08-25",{"date":297,"type":21},"2026-12-31",{"name":299,"class":128},"University of Calgary",{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":16,"minAge":65,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":68,"phases":309,"briefSummary":310,"conditions":311,"keywords":316,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":324,"locationsCount":326},"100640267","intensive-neurofeedback-protocol-for-children-with-adhd-a-proof-of-concept-study-comparing-iapf-personalized-and-standard-theta-beta-ratio-training-100640267","NCT07595783","Intensive-neurofeedback Protocol for Children With ADHD: A Proof-of-concept Study Comparing iAPF-personalized and Standard Theta-beta-ratio Training","Inclusion Criteria:\n\n* Children aged 6-13 years. Confirmed ADHD diagnosis (ICD 10: F90.0, F90.1, or F98.8)\n* German-speaking children with normal or corrected vision.\n\nExclusion Criteria:\n\n* Children with neurological disorders (e.g., Epilepsy)\n* Children without an ADHD diagnosis\n* Caregivers with inability to provide informed consent or complete questionnaires\n* Participation in neurofeedback that was conducted in the year prior to the intended participation or is still ongoing.\n\nThe intake of medication or psychotherapeutic treatments and ICD-10 diagnosis are queried at T1, T2 and T3. These are recorded as control variables and are not exclusion criteria. The medication intake was kept constant during the NF training.","13 Years",{"count":308,"type":21},40,[108],"The first aim of this clinical trial is to test the feasibility and signal validity of a new approach to neurofeedback training (NF) using intensive EEG-based theta-beta NF for children with ADHD in the context of NF camps during school holidays. The second aim is to compare the efficacy of two neurofeedback protocols in reducing ADHD symptoms. Previous study results highlight that children with ADHD frequently show increased Theta-Beta-Ratios (TBR) in the qEEG, probably associated with attention difficulties, which may be ameliorated following neurofeedback training. However, the current state of research shows heterogenous findings regarding the efficacy of standard TBR NF for children with ADHD. Further study results suggest that personalized NF training protocols, based on the individual alpha peak frequency (iAPF), may be more effective in reducing ADHD symptoms than standardized ones.\n\nTherefore, in this proof-of-concept study of children with ADHD a standard TBR NF protocol is compared with an iAPF-personalized TBR NF (iAPF-TBR NF) protocol (based on the previously obtained iAPF). The study is designed as a randomized controlled intervention trial (RCT) with three assessment points (pre \\[T1\\], post \\[T2\\] and 6-month follow-up \\[T3\\]). Primary endpoints include the reduction of ADHD symptoms assessed by parent-, teacher- and self-report questionnaires. Furthermore, it is hypothesized that NF training is associated with better performance in a sustained attention and executive function test and a reduced TBR in qEEG, particularly following iAPF-TBR NF.\n\nThe main questions are:\n\n* Is it feasible to train groups of up to 12 children with two sessions NF per day for an eight-day-period during their school holidays?\n* Does iAPF-TBR NF provide a valid neuromodulatory signal compared to the standard-TBR-NF protocol? Do the frequency boundaries demonstrate spectral stability across the 16 training sessions?\n* Does the personalized iAPF-TBR NF training reduce ADHD symptoms measured immediately after the training more than standard-TBR-NF training? (comparison T2-T1)\n* Does the personalized iAPF-TBR NF training reduce ADHD symptoms measured 6 months after the NF training more than standard TBR-NF training? (comparison T3-T1)\n* Does the reduction in ADHD symptoms measured immediately after the NF-training persist until the 6-month follow-up? Do possible differences between iAPF-TBR NF training and standard TBR NF training remain? (comparison T3-T2)\n\nPost-hoc analyses of the courses are carried out. In addition, selectivity analyses will be carried out for clinical subgroups (e.g. different ADHD profiles)",[25,312,313,314,315],"Inattention","Hyperactivity","Impulsivity","Executive Dysfunction",[317,25,318],"EEG-neurofeedback","children","2026-05-12",{"date":263,"type":36},{"date":322,"type":36},"2024-07-09",{"date":297,"type":21},{"name":325,"class":128},"Bielefeld University",2,{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":16,"minAge":335,"maxAge":103,"enrollmentInfo":336,"targetDuration":4,"studyType":68,"phases":337,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":44},"100631701","adhdme-targeting-self-esteem-in-youth-with-adhd-100631701","NCT07504107","ADHD&me: Targeting Self-esteem in Youth With ADHD","ADHD&me: a Randomized Controlled Trial to Target Self-esteem in Youth With ADHD","ADHD&me","Inclusion Criteria:\n\n* 16-25 years old.\n* Official ADHD diagnosis, that is confirmed by research team using the clinical interview MINI-S.\n* Low self-esteem, determined through a structured and multi-step procedure to minimize subjectivity:\n\n  * Referral by clinician. Clinicians from participating institutions identify potential participants. To ensure a uniform understanding of the study population and inclusion criteria, all clinicians receive specific training. The researcher(s) conduction the baseline assessment are also familiar with these training materials, so that the inclusion procedure is applied consistently.\n  * Telephone screening. Two items from the Rosenberg Self-Esteem Scale (RSES; Rosenberg, 1965) are administered (\"At times I think I am no good at all\" and \"All in all, I am inclined to think I am a failure\"). A score of 3 (agree) or 4 (strongly agree) on either of these items is considered indicative of low self-esteem.\n  * Baseline confirmation. During the baseline measurement, the full Rosenberg Self-Esteem Scale is administered. A cutoff score of \\\u003C 15 is used as an objective reference point. This score is combined with a standardized clinical interview conducted by a trained researcher psychologist. At the ADHD section of the MINI-S at the baseline measurement, participants are asked by the researcher psychologist how their symptoms interfere with domains such as work, study, relationships, and self-esteem. If self-esteem is not mentioned, a follow-up question will be asked: \"Many people with ADHD feel their symptoms affect their self-esteem, for example due to repeated negative feed- back, feeling like they are not good at things, or failing short. Do you recognize this in yourself\"? Based on the participant's response, the trained researcher psychologist interviewer forms a professional, clinical impression of whether there are indicators of persistently low self-esteem (i.e.,insecurity, fear of failure, strong reactions to criticism, perfectionism, distress related to ADHD symptoms). This clinical assessment approach is based on examples provided by the Diagnostic Interview for ADHD in Adults (DIVA-2-NL; Kooij \\& Francken, 2010). In all doubtful cases, the inclusion decision will be discussed in consensus meetings with the research team and supervisor, ensuring high inter-rater reliability.\n* Pharmacological treatment for ADHD is allowed, but medication dose should be stabilized for a minimum of 4 weeks at baseline measurement (T0). Although changes in ADHD medication during the study are not preferred, they may occur in practice. Any such changed will be carefully documented.\n\nExclusion Criteria:\n\n* Concurrent psychopathology that requires immediate attention (e.g., severe depression, suicidal thoughts\u002Frisk of suicide (as determined by the referring therapist and\u002For research team). Other comorbidity is allowed.\n* Undergoing any concurrent psychological treatment during the study, including any form of therapy for ADHD (e.g., CBT for planning skills). Psychoeducation completed prior to the study entry is allowed, but not during the study.\n* Low self-esteem that directly stems from a traumatic experience, which would indicate the need for trauma-specific treatment. This will be determined by the referring therapist. If someone in addition suffers from low self-esteem due to the ADHD symptoms, an appropriate timing of each treatment will be dis- cussed by the referring therapist and potential client.\n* IQ \\\u003C 80 assessed with two WAIS-IV subscales (Wechsler, 2008): Vocabulary and Block Design.\n* Severe substance use (as determined by the referring therapist and\u002For research team).\n* Confirmed Autism Spectrum Disorder (ASD) diagnosis. This also applies when the referring therapist indicates that an ASD diagnosis is very likely, even if it has not yet been established. Since ASD diagnostic procedures are time-consuming and fall outside the scope of this research project, formal ASD assessment will not be conducted within this study.\n\nNote. If included participants receive unforeseen supportive sessions outside the research setting, or if unforeseen medication changes occur during the study, these will be documented and considered during the analysis.","16 Years",{"count":20,"type":21},[108],"The goal of this clinical trial is to learn whether the ADHD\\&me (ADHD\\&ik) intervention can improve self-esteem in youth aged 16-25 years with Attention Deficit Hyperactivity Disorder (ADHD). The ADHD\\&me program is a cognitive behavioral therapy (CBT)-based intervention designed to help people with ADHD to develop a more positive view of themselves in their transition to adulthood.\n\nThe main questions it aims to answer are:\n\n* Does the ADHD\\&me intervention improve self-esteem in youth with ADHD, and are these effects maintained over time?\n* Does the intervention also improve related outcomes, such as masking of ADHD-related behaviors and co-occurring mental health symptoms including anxiety, depression, and stress?\n\nIn this RCT, participants are assigned either to immediate treatment or to a waitlist control condition, with the latter receiving the intervention after an eight-week delay.\n\nParticipants will:\n\n* Take part in seven individual therapy sessions according to the ADHD\\&me intervention.\n* Complete questionnaires about self-esteem, masking of ADHD-related behaviors, ADHD symptoms, and co-ccurring mental health symptoms at several time points.\n* Complete short daily assessments (ecological momentary assessment) during one week at the start of the study and one week after the intervention or waitlist period to report momentary self-esteem, emotions, distress, and activities.",[25],[25,341,342,343,344,345,346,347,348],"Self-esteem","Masking","Comorbidity","Young adults","Youth","CBT","Intervention","RCT","2026-05-11",{"date":351,"type":36},"2026-05-14",{"date":353,"type":36},"2026-03-25",{"date":355,"type":21},"2028-03-31",{"name":357,"class":128},"Universiteit Leiden",{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":102,"sex":16,"minAge":249,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":68,"phases":368,"briefSummary":369,"conditions":370,"keywords":373,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":44},"100596199","testing-a-measurement-feedback-app-to-improve-data-quality-supervision--outcomes-in-behavioral-health-100596199","NCT07042347","Testing a Measurement Feedback App to Improve Data Quality, Supervision & Outcomes in Behavioral Health","RCT of a Measurement Feedback App to Improve Data Quality, Supervision & Outcomes in Behavioral Health","Footsteps","Inclusion Criteria:\n\n* Aides must be working with at least one client in school who meets the following criteria: 1) between 3-17 years, 2) has a diagnosis associated with a challenging behavior (e.g., autism spectrum disorder, attention deficit hyperactivity disorder, oppositional defiant disorder) as indicated on their treatment plan, and 3) receiving 1:1 aide support.\n* Supervisors must be employed by a community behavior health agency and supervise a participating aide. The investigators will recruit supervisors in dyads and not triads (i.e., no supervisors with two \\[or more\\] aides) to ensure there are 30 supervisor-aide dyads in total).\n\nExclusion Criteria:\n\n* Aides who participated in the pilot trial of the Footsteps will be excluded from participating to recruit a sample naïve to Footsteps and the control app.",{"count":367,"type":21},200,[108],"The goal of this clinical trial is to test whether a smartphone-based data collection and feedback application (\"Footsteps\") improves the quality of behavioral data collected by one-to-one aides and leads to better youth mental health outcomes in school-aged youth (ages 4-17) who receive one-to-one support in schools.\n\nThe main questions it aims to answer are:\n\n1. Does the Footsteps app improve aides' data collection quality (i.e., consistency, timeliness, and completeness)?\n2. Does Footsteps use lead to improved youth behavioral health outcomes (e.g., SDQ, YTP scores)?\n3. Does Footsteps improve communication and supervision processes between aides and clinical supervisors?\n\nResearchers will compare aides using Footsteps to those using a \"data collection only\" control app to see if Footsteps leads to higher quality data collection, enhanced supervisory communication, and better youth outcomes.\n\nParticipants will:\n\n* Use either Footsteps or a control app to record de-identified data on one client's behaviors and skills over 12 weeks\n* Complete biweekly online surveys about data collection experiences, youth progress, and aide-supervisor communication\n* Participate in a virtual intake and post-trial meeting\n* (For a subset) Participate in a 30-45 minute qualitative interview about their experience using the app",[146,371,25,372],"Challenging Behavior","Oppositional Defiant Disorder",[374,375,376,377,378],"data collection","Behavioral Health Technician (BHT)","behavioral economics","implementation science","supervisory processes","2026-05-07",{"date":381,"type":36},"2026-05-08",{"date":383,"type":36},"2026-04-08",{"date":385,"type":21},"2028-06-30",{"name":387,"class":128},"University of Pennsylvania",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":277,"minAge":249,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":68,"phases":398,"briefSummary":399,"conditions":400,"keywords":403,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":44},"100593042","expectant-moms-managing-attention-deficit-hyperactivity-disorder-100593042","NCT07001293","Expectant Moms Managing Attention-Deficit\u002F Hyperactivity Disorder","Supporting Expectant Mothers With ADHD Through the Transition to Parenthood: A Pilot RCT","MomMA","Inclusion Criteria:\n\n1. meets full DSM-5 criteria for ADHD\n2. is between 14- and 22-weeks of gestation\n3. 18 years of age or older\n4. English speaking\n5. Lives in Pennsylvania\n\nExclusion Criteria:\n\n1. substance use disorders requiring dual diagnosis treatment\n2. intellectual disability\n3. bipolar disorder, psychosis, and major depressive disorder with suicidal ideation\n4. the following high complexity medical conditions during pregnancy: maternal cancer, multiples, placenta accreta, and\u002For fetus known to have a severe congenital condition",{"count":397,"type":21},80,[108],"The goal of this study is to test a behavioral program for pregnant individuals with ADHD. This behavioral program focuses on skills for managing ADHD and related symptoms in pregnancy and postpartum.\n\nThis pilot effectiveness-implementation trial aims to (1) preliminarily evaluate the MomMA behavioral intervention compared to treatment as usual (TAU) on clinical outcomes and (2) evaluate implementation outcomes, including feasibility and acceptability of clinic screening within existing OB workflows; assessment and intervention protocols; provider training\u002Ffidelity to manual; and all other study protocols from the perspective of real-world providers and participants.",[25,401,402],"Perinatal","Behavioral Intervention",[25,404,405,402,406,407,408],"Pregnancy","Perinatal Mental Health","Parenting","Emotion Regulation","Executive Functioning","2026-05-05",{"date":379,"type":36},{"date":412,"type":36},"2026-04-26",{"date":414,"type":21},"2028-05-31",{"name":416,"class":128},"University of Pittsburgh",{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":16,"minAge":424,"maxAge":248,"enrollmentInfo":425,"targetDuration":4,"studyType":68,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":44},"100477089","central-executive-training-and-parent-training-for-adhd-100477089","NCT05492422","Central Executive Training and Parent Training for ADHD","Evaluating the Efficacy of Sequenced Central Executive and Behavioral Parent Training for Children With ADHD","Inclusion:\n\n1. Children ages 8-12 with principal ADHD diagnoses (via K-SADS); and\n2. parent AND teacher ratings in clinical\u002Fborderline range based on age and sex on ADHD Rating Scale (ADHD-5) or Behavior Assessment Scale for Children (BASC-3) Attention Problems\u002FHyperactivity subscales (i.e., 90th percentile or higher based on both informants).\n\nAll DSM-5 ADHD presentations will be eligible.\n\nExclusion:\n\n1. gross neurological, sensory, or motor impairment;\n2. history of seizure disorder, psychosis, bipolar, or severe dysregulation disorders that may interfere with participation (e.g., disruptive mood dysregulation, intermittent explosive, reactive attachment, substance use);\n3. intellectual disability or Wechsler Intelligence Scale for Children (WISC-V) short-form standard score \\\u003C70;\n4. conditions requiring acute intervention, e.g., active suicidality; and\n5. non-English speaking child or parent.","8 Years",{"count":367,"type":21},[108],"The goal of the current project is to combine two evidence- based treatments for school-aged children with ADHD: Central Executive Training (CET) and Behavioral Parent Training (BPT). CET is a computerized training intervention that improves ADHD symptoms and academic functioning by improving children's working memory abilities. BPT is a therapeutic intervention that improves family functioning and child oppositional-defiant (ODD) symptoms by changing parenting behaviors. Their combined use is expected to provide complementary and additive benefits, particularly if CET is delivered before BPT.",[25],{"date":379,"type":36},{"date":431,"type":36},"2022-10-03",{"date":433,"type":21},"2027-08-01",{"name":435,"class":128},"Florida State University",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":16,"minAge":65,"maxAge":443,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":446,"conditions":447,"keywords":448,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":44},"100590762","advancing-identification-of-circadian-delay-in-adhd-youth-associations-with-clinical-heterogeneity-and-cognition-100590762","NCT06971640","Advancing Identification of Circadian Delay in ADHD Youth: Associations With Clinical Heterogeneity and Cognition","CIRCA","Inclusion Criteria:\n\n1. Child ages 6-9\n2. Meet criteria for a primary psychiatric diagnosis of DSM-5 ADHD, any presentation\n3. Intellectual functioning \\>80\n4. Healthy (i.e., no major medical problems)\n5. If applicable, willingness to suspend use of melatonin during the study period\n\nExclusion Criteria:\n\n1. Meet DSM-5 criteria for psychosis, bipolar, or autism spectrum disorders\n2. Diagnosis of occult sleep disorders, including sleep apnea or restless leg syndrome\n3. Medication for sleep other than melatonin\n4. Plans to initiate stimulant medication during the study period","9 Years",{"count":445,"type":21},250,"The purpose of this study is to better understand sleep and circadian functioning in children with ADHD using home-based measures, parent report, and a lab based melatonin assessment. Investigators will also examine how sleep relates to psychiatric health and cognition among children with ADHD. The investigator for this study is Dr. Jessica Lunsford-Avery from the Department of Psychiatry.",[147,25],[25,449,450,451],"attention deficit disorder with hyperactivity","circadian rhythm","dim light melatonin onset","2026-05-04",{"date":409,"type":36},{"date":455,"type":36},"2025-05-28",{"date":457,"type":21},"2029-11",{"name":459,"class":128},"Duke University",{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":16,"minAge":468,"maxAge":248,"enrollmentInfo":469,"targetDuration":4,"studyType":68,"phases":471,"briefSummary":472,"conditions":473,"keywords":474,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":44},"100462296","impact-of-parental-emotion-regulation-on-the-treatment-of-adhd-100462296","NCT05299814","Impact of Parental Emotion Regulation on the Treatment of ADHD","The Impact of Parental Emotion Regulation Capacity on Behavioral Treatment for Pediatric ADHD","PERS","Inclusion Criteria:\n\n* Parent of a child ages 5-12 with ADHD\n* Parent must report that the child has at least a mild level of symptoms at home of Oppositional Defiant Disorder (ODD) on the Disruptive Behavior Disorder Rating Scale (DBDRS)\n\nExclusion Criteria:\n\n1. Not being the parent of a child ages 5-12 who meets diagnostic criteria for ADHD.\n2. Non English Speaking\n3. the child with ADHD has a diagnosis of intellectual delay or has prominent autistic traits\n4. Another child in the same family participating in this study already\n5. Parent does not have a smartphone or tablet device to complete EMA ratings or does not reside with child for the majority of the time.","5 Years",{"count":470,"type":21},65,[108],"Aim: To examine if parental emotion regulation (ER) moderates the response to parent training interventions.\n\nH1: Reduced parental ER capacity will predict diminished efficacy for behavioral parent training to improve negative parenting behavior (NPB) and behavior problems in offspring with ADHD.\n\nH2: Increased parental emotional reactivity will predict diminished efficacy for behavioral parent training to improve negative parenting behavior (NPB) and behavior problems in offspring with ADHD.",[25],[475],"oppositional behaviors, conduct problems","2026-05-01",{"date":379,"type":36},{"date":479,"type":36},"2017-04-13",{"date":481,"type":21},"2026-10-31",{"name":483,"class":128},"Milton S. Hershey Medical Center",{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":16,"minAge":424,"maxAge":249,"enrollmentInfo":491,"targetDuration":4,"studyType":68,"phases":493,"briefSummary":496,"conditions":497,"keywords":499,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":44},"100597667","phase-1-a-clinical-trial-of-iron-supplementation-for-youth-with-adhd-and-restless-sleep-100597667","NCT07061470","A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep","RestEaze: A Novel Wearable Device and Mobile Application to Improve the Diagnosis and Management of Restless Sleep in Pediatric Patients With Attention Deficit\u002FHyperactivity Disorder, Phase II","Inclusion Criteria:\n\n* clinically diagnosed with ADHD\n* have blood ferritin level below 50ng\u002FmL\n* have parent- or self-reported restless sleep\n\nExclusion Criteria:\n\n* presence of any chronic medical or genetic condition that could impact iron metabolism\n* presence of moderate to severe Obstructive Sleep Apnea\n* having received Iron supplementation treatment within the past 3 months\n* having blood ferritin level indicative of anemia that requires immediate treatment",{"count":492,"type":21},70,[494,495],"PHASE1","PHASE2","The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are:\n\nDoes 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and\u002For objectively measured attention more than placebo?\n\nResearchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD.\n\nParticipants will:\n\n* Take iron supplements every day for 3 months\n* Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention\n* Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment",[25,498],"Sleep Problems",[25,500,501,502,503,504],"iron supplements","sleep","restlessness","attention","restless legs syndrome","2026-04-30",{"date":452,"type":36},{"date":508,"type":21},"2027-03-01",{"date":510,"type":21},"2027-07-31",{"name":512,"class":128},"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":102,"sex":16,"minAge":468,"maxAge":219,"enrollmentInfo":521,"targetDuration":4,"studyType":68,"phases":523,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":537,"locationsCount":326},"100573218","a-pilot-study-of-a-remote-adhd-monitoring-program-100573218","NCT06743425","A Pilot Study of a Remote ADHD Monitoring Program","A Pilot Study of a Remote Attention-Deficit\u002FHyperactivity Disorder Monitoring Program (RAMP) for Children in Rural Areas","RAMP","Inclusion Criteria:\n\nThe child must\n\n* be under the care of a participating provider\n* be aged 5-11 at enrollment\n* have a diagnosis of ADHD\n* be initiating stimulant medication for treatment for the first time or have not received stimulant medication for the last 6 months\n* be attending in-person elementary school\n\nThe Primary caregiver must\n\n* be willing and legally able to give consent\n* have access to a smartphone\n* be English-speaking\n* reside with the child at least 3 days per week\n* complete an initial symptom assessment prior to starting stimulant treatment and be willing to provide a copy to the study team\n\nThe provider must\n\n* manage ADHD care in patients age 5-11 years\n* provide informed consent\n* agree to use the RAMP platform if they care for patients randomized to use it\n* agree to provide information to potential participants about the study and contact the research coordinator if interested\n\nExclusion Criteria:\n\nChild:\n\n* has serious mental health comorbidities (Children with depression, anxiety, oppositional defiant disorder will be permitted to participate. Children with schizophrenia, bipolar disorder, conduct disorder and those who have been hospitalized for any mental health condition will be excluded from the study.)\n* has severe neurodevelopment disorders (Children with well-controlled seizure disorders will be permitted to participate.)\n* is currently receiving, or previously received, atypical antipsychotic medication treatment\n* is or becomes pregnant",{"count":522,"type":21},36,[108],"RAMP is a pilot study examining the use of an Attention-Deficit\u002FHyperactivity Disorder (ADHD) Monitoring Program during the early stages of treating ADHD in children living in rural settings. This trial will enroll 36 caregiver\u002Finfant dyads across 2 sites and will evaluate feasibility endpoints rather than clinical outcomes. Enrolled participants will be randomized 1:1 to the intervention group (RAMP reports) or control group (digital education handouts). The study duration is 10 months, including start-up, enrollment and intervention, and data analysis and manuscript submission.",[526,25],"Attention-deficit\u002FHyperactivity Disorder",[528,529,530],"Rural health","Vanderbilt","Text-based Symptom Reporting","2026-04-27",{"date":533,"type":36},"2026-04-28",{"date":535,"type":36},"2025-02-04",{"date":50,"type":21},{"name":538,"class":539},"IDeA States Pediatric Clinical Trials Network","NETWORK",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":102,"sex":16,"minAge":249,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":44},"100633840","five-digits-test---validation-of-a-neuropsychological-test-of-inhibition-for-patients-with-neuropsychiatric-conditions-100633840","NCT07531914","Five Digits Test - Validation of a Neuropsychological Test of Inhibition for Patients With Neuropsychiatric Conditions","Inclusion Criteria:\n\n* age 18 and above\n* Diagnosed with a ADHD or Autism, alternatively under examination these diagnoses\n\nExclusion Criteria:\n\n* Addiction of alcohol or other substances\n* Not speaker of Swedish to such extent that cannot read or comprehend the informed consent forms\n* On sedatives, such as sleep or pain medication\n* Not being able to participate in a neuropsychological examination, or to give informed consent",{"count":547,"type":21},150,"Neuropsychiatric conditions such as Attention Deficit Hyperactivity Disorder (ADHD) and autism are characterized by specific deficits in cognitive functions. Thus, neuropsychological assessment is a critical part of the diagnostic process for these conditions. Inhibition is a specific function of interest during these examinations, since it is often affected in patients with ADHD and\u002For autism. The Five Digits Test (FDT) is a newly developed test measuring inhibition, without requirements of reading ability, and only limited requirements of language proficiency.\n\nThe aim of this study is to investigate the validity of the FDT in patients with neuropsychiatric conditions. The FDT will be validated using the following research questions:\n\n1. Is the FDT equivalent to the standard neuropsychological test of inhibition, the Color-Word Interference Test from the Delis-Kaplan Executive Function System in patients with neuropsychiatric conditions? (Convergent validity)\n2. Is the FDT consistent with self-assessment of inhibition and behavioral regulation in every day life using the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A)? (Ecological validity)\n3. Are there differences in validity in the first two research questions due to language background or due to reading and writing difficulties?\n4. Are there differences between patients with neuropsychiatric conditions and healthy controls in the performance of the FDT?",[146,25],[551,25,146,552],"Neuropsychological Assessment","Inhibition","2026-04-13",{"date":555,"type":36},"2026-04-15",{"date":557,"type":36},"2026-01-21",{"date":559,"type":21},"2027-12",{"name":561,"class":128},"Umeå University",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":16,"minAge":424,"maxAge":219,"enrollmentInfo":569,"targetDuration":4,"studyType":68,"phases":570,"briefSummary":571,"conditions":572,"keywords":573,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":44},"100599425","spanish-language-executive-function-intervention-for-children-with-autism-andor-adhd-100599425","NCT07084324","Spanish-language Executive Function Intervention for Children With Autism and\u002For ADHD","Evaluating a Spanish-language Executive Functioning Intervention for Children With Autism and\u002For ADHD and Their Families","Inclusion Criteria:\n\n* Child is 8-11 years old.\n* Child meets DSM-5 criteria for Autism Spectrum Disorder and\u002For ADHD\n* Child has verbal skills at a 7-year-old level or greater (as measured by WASI Vocabulary and Similarities subtests)\n* Caregiver endorses at least one of the following executive functioning problems:\n* Difficulty accepting feedback or criticism.\n* Difficulty handling frustration.\n* Difficulty starting non-preferred activities.\n* Frequent meltdowns.\n* Not stopping a behavior after being told to stop.\n* Shutting down in the face of a challenge.\n* Caregiver is at least 18 years old.\n* Caregiver identifies Spanish as their preferred or primary language.\n\nExclusion Criteria:\n\n\\- Individuals will be excluded only if they do not meet one or more of the inclusion criteria listed above.",{"count":308,"type":21},[108],"The goal of this clinical trial is to learn whether the Spanish-language version of Unstuck and On Target (SL-Unstuck), an executive functioning (EF) intervention, is feasible, acceptable, and effective for Spanish-speaking caregivers and their neurodivergent children (ages 8-11) in the U.S.. The main questions it aims to answer are:\n\n* Is SL-Unstuck acceptable to Spanish-speaking caregivers and children?\n* Does SL-Unstuck improve child EF, caregiver EF knowledge, and caregiver strain?\n\nResearchers will compare families randomly assigned to immediate SL-Unstuck versus waitlist control to see if participating in the intervention improves EF and family outcomes.\n\nParticipants will:\n\n* Attend 8 weekly SL-Unstuck sessions at a clinic (parallel child and caregiver groups)\n* Complete pre- and post-intervention assessments on child EF, caregiver strain, and satisfaction\n* Participate in a focus group to share feedback on the intervention",[146,25],[574,575,25,576],"executive functioning","autism","Hispanic\u002FLatine","2026-03-30",{"date":579,"type":36},"2026-04-03",{"date":581,"type":36},"2025-07-15",{"date":583,"type":21},"2030-03",{"name":585,"class":128},"University of Colorado, Denver",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":593,"minAge":249,"maxAge":594,"enrollmentInfo":595,"targetDuration":4,"studyType":68,"phases":597,"briefSummary":598,"conditions":599,"keywords":600,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":326},"100545160","testing-a-new-method-to-improve-informed-consent-in-prison-research-100545160","NCT06378281","Testing a New Method to Improve Informed Consent in Prison Research","Spark BATIR","Inclusion Criteria:\n\n* inclusion in the parent-RCT\n* age ≥ 18 years\n* good command of French\n* absence of acute psychiatric disorder\n* providing written informed consent for study participation in the parent-RCT\n\nExclusion Criteria:\n\n\\- none.","MALE","65 Years",{"count":596,"type":21},100,[108],"Understanding of informed consent is often limited in prison, due to unique challenges faced by detained people. This study will test a modified \"teach-to-goal\" informed consent process compared to standard procedures. Conducted within a larger study on psychiatric outcomes, it aims to enhance ethical practices for vulnerable populations.",[25],[601,602,603],"Informed consent","Prison","Ethics","2026-03-13",{"date":606,"type":36},"2026-03-17",{"date":608,"type":36},"2024-05-01",{"date":610,"type":21},"2026-09-30",{"name":612,"class":128},"Stéphanie Baggio",{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":16,"minAge":249,"maxAge":594,"enrollmentInfo":621,"targetDuration":4,"studyType":68,"phases":622,"briefSummary":623,"conditions":624,"keywords":625,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":44},"100503981","phase-3-benefits-of-adhd-treatment-in-detained-people-100503981","NCT05842330","Benefits of ADHD Treatment in Detained People","Benefits of In-prison OROS-methylphenidate vs. Placebo Treatment in Detained People With Attention-deficit\u002FHyperactivity Disorder: A Randomized Controlled Trial","BATIR","Inclusion Criteria:\n\n* age between 18 and 65\n* good command of French\n* stay in prison approx. 4 months at eligibility visit\n* endorsing clinical diagnostic criteria for DSM-5 ADHD\n* providing written informed consent\n\nExclusion Criteria:\n\n* presence of an acute uncontrolled comorbid psychiatric disorder\n* medical contraindication to stimulant prescription\n* potential adverse interaction with another medication\n* already receive ADHD treatment",{"count":547,"type":21},[70],"Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD treatment has been neglected in prison. This project will test the efficacy of ADHD treatment using a randomized controlled trial.",[25],[602,626,627,628],"Health care","Adherence to treatment","Recidivism",{"date":606,"type":36},{"date":631,"type":36},"2024-01-01",{"date":633,"type":21},"2027-10-30",{"name":612,"class":128},{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":102,"sex":16,"minAge":643,"maxAge":468,"enrollmentInfo":644,"targetDuration":646,"studyType":22,"phases":4,"briefSummary":647,"conditions":648,"keywords":649,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":659,"locationsCount":44},"100626850","identification-of-early-biomarkers-of-pre-school-adhd-100626850","NCT07440992","Identification of Early Biomarkers of Pre-school ADHD","Identification of Early Biomarkers of Pre-school ADHD: Pilot Study for the Development of a Clinical and Research Platform Dedicated to Early Detection and Intervention","Bio-PreTDAH","Inclusion Criteria:\n\n* For ADHD subjects:\n* Children aged between 3.0 and 5 years and 11 months, with clinical criteria for ADHD, according to DSM 5.\n* Children followed in the Child and Adolescent Psychiatry Department of Robert Debré Hospital.\n* Children naïve to pharmacological treatment for ADHD\n\nFor control subjects:\n\n* Children between 3.0 - 5 years and 11 months\n* No known condition or disease affecting development and behavior\n\nExclusion Criteria:\n\n* For both groups\n* Intellectual disability according to DSM 5 +- WPPSI IV \\\u003C 70\n* Refusal of the child or one of his parents or representatives of parental authority.\n* Patient under AME or not affiliated to a social security scheme","3 Years",{"count":645,"type":21},60,"12 Months","ADHD affects around 5% of children and manifests itself as hyperactivity, attention difficulties and motor control and balance problems. The prevalence of ADHD is particularly high in certain populations, affecting up to 25-30% of children born prematurely and around 20% of children with neurological conditions such as epilepsy. This disorder is officially diagnosed from the age of 6, according to current criteria. However, its clinical manifestations appear much earlier, having a significant impact on all aspects of the child's life, particularly in the most severe forms, which are often unrecognised due to a lack of clinical resources, and therefore without appropriate treatment.\n\nThe creation of a platform dedicated to children at risk of ADHD will enable specific clinical expertise to be developed, with the aim of proposing early targeted interventions and positively influencing the development of their trajectory. This platform will also aim to develop new diagnostic methods, based on indirect measures of attentional and executive processes, balance and the development of a risk measurement scale. This development is essential, as the assessment tools currently available lack specificity.\n\nIn order to demonstrate the reliability of the innovative diagnostic methods proposed, a comparative pilot study between children from the first clinical cohort (N=30) and a group of healthy children of the same age (N=30) will be carried out. This will enable us to study the discrimination of our tools and make any necessary adjustments. This pilot study also includes a longitudinal re-evaluation, at 12 months, of the children in the ADHD cohort, in order to study changes in these biomarkers over time.",[25],[650,651,25],"Psychiatry","pediatry","2026-02-25",{"date":654,"type":36},"2026-02-27",{"date":656,"type":21},"2026-03-01",{"date":658,"type":21},"2028-03-01",{"name":660,"class":128},"Assistance Publique - Hôpitaux de Paris",{"id":662,"slug":663,"hasResults":12,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":667,"eligibilityCriteria":668,"healthyVolunteers":102,"sex":16,"minAge":249,"maxAge":104,"enrollmentInfo":669,"targetDuration":4,"studyType":68,"phases":670,"briefSummary":671,"conditions":672,"keywords":673,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":44},"100621909","improving-adhd-symptoms-and-quality-of-life-through-diet-100621909","NCT07376746","Improving ADHD Symptoms and Quality of Life Through Diet","Improving ADHD Core Symptoms and Individual Quality of Life With Dietary APproaches Through Microbiota-Gut-Brain Signalling","ADAPT","ADHD Group Inclusion Criteria:\n\n1. Be able to give written informed consent\n2. Should be stable for 4 weeks on psychopharmacological medication or without medication\n3. Should have an established diagnosis of ADHD or ADD as the main mental disorder diagnosis. This will be validated by the ADHD diagnostic criteria after DSM-5, with the DIVA interview.\n4. Aged 18-50 years\n5. Fluency in English language\n\nControl Group Inclusion Criteria\n\n1. Be able to give written informed consent\n2. Should be stable for 4 weeks on any medication for physical health or without medication\n3. Should not currently taking psychopharmacological medicine or discontinued psychopharmacological medicine in the past 6 months (due to relapse risk)\n4. Should NOT have an established diagnosis or clinical symptoms of ADHD or ADD. This will be validated using with the ASRS-6 (\\\u003C 4)\n5. Should not have a diagnosis of ASD as indicated by self-report.\n6. Not have current, or in the past 2 years, symptoms or diagnosis of a depressive disorder, bipolar spectrum disorder, OCD, PTSD, generalised anxiety disorder, severe alcohol or illegal drug dependency, psychotic disorder, anorexia nervosa, and bulimia nervosa\n7. Not have current symptoms or diagnosis of a panic disorder or social anxiety disorder that is not currently being treated by a psychotherapist or other mental health care professional\n8. Aged 18-50 years\n9. Fluency in English language\n\nADHD and Control Group Exclusion criteria:\n\n1. Current severe depressive (PHQ-9\\>15), manic or psychotic episode, acute suicidality or suicide attempt in the past 3 months, current severe alcohol and illegal drug dependency as determined by the MINI Psychiatric Interview or clinical diagnosis.\n2. Pregnant, breastfeeding, or planning to be pregnant.\n3. Habitual fibre intake exceeding 25g\u002Fday.\n4. Allergy to intervention foods.\n5. Allergy to local anaesthesia (only if opting for the skin punch).\n6. Taking anticoagulant medication or have coagulation disorder like haemophilia (only if opting for the skin punch).\n7. Have a BMI below 18.5 kg\u002Fm2.\n8. Current diagnosis or symptoms of anorexia nervosa or bulimia nervosa, as determined by clinical diagnosis or on the MINI.\n9. Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic) or any condition which contraindicates, in the investigator's judgement, entry to the study.\n10. Taking antibiotics in the past month (washout period of 1 month is required).\n11. Taking medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; to include anti-inflammatory drugs, corticosteroids, laxatives, enemas, anti-coagulants, and over-the counter non-steroidal analgesics. Participants should have a wash-out period of one month.\n12. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.\n13. Participants receiving treatment involving experimental drugs. Washout period of one month is required.\n14. Current prebiotic or probiotic supplement use (a wash-out period of 4 weeks after cessation will allow entry to the study).\n15. Previous participation in the Diet Study (APC150)\n16. Uncorrected vision.\n17. A history of any other condition affecting cognitive function (besides ADHD or ASD for ADHD group participants).\n\nThe specific exclusion criteria for electroencephalography (EEG) recording for both the ADHD and Control groups are as follows:\n\n1. Left-handedness,\n2. Non-removable medical devices such as pacemakers, hearing aids, cochlear implants, or deep brain stimulators,\n3. Hairstyles that prevent access to the scalp, and\n4. Skin conditions on the scalp.\n\nParticipants who meet these exclusion criteria for the EEG portion of the study will still be included in the overall study but will not undergo EEG recording and will instead complete neurocognitive tasks outside of EEG recording.",{"count":367,"type":21},[108],"The goal of this randomised controlled trial is to evaluate whether a specific dietary intervention can reduce core symptoms of Attention-Deficit\u002FHyperactivity Disorder (ADHD) in adults aged 18 to 50 years. The study also aims to understand how changes in diet may influence quality of life, neurocognitive function, and gut-brain signaling through the microbiota.\n\nThe main questions it aims to answer are:\n\n1. Does a high-fiber, fermented food-based diet reduce ADHD core symptoms over a 12-week period, as measured by the Conners' Adult ADHD Rating Scale (CAARS)?\n2. Does the diet improve neurocognitive function, mood, food reward, individual goals, and other quality-of-life outcomes?\n3. How does the diet affect gut microbial composition, inflammation, and stress-related biomarkers?\n4. Is the diet well-accepted and feasible to follow?\n\nResearchers will compare a combination intervention diet (high in fiber and fermented foods) to a control diet based on general healthy eating guidelines to assess differences in symptom improvement and biological outcomes.\n\nParticipants will:\n\n1. Complete six study visits over a 24-week period (screening, baseline, weeks 4, 8, 12, and optional follow-up at week 24).\n2. Be randomly assigned to one of two dietary groups after baseline assessments.\n3. Provide stool, saliva, urine, and blood samples at multiple timepoints.\n4. Undergo cognitive testing and EEG recording to assess brain function.\n5. Wear a wristband to track sleep and activity patterns.\n6. Use a nutrition app to log dietary intake and receive weekly dietary support.\n7. Complete validated questionnaires on ADHD symptoms, mood, eating behavior, gastrointestinal health, sleep, and lifestyle factors. Feasibility and acceptability of following the diet will also be self-reported.\n\nThis study includes both adults diagnosed with ADHD and matched controls without a psychiatric condition to better understand the mechanisms and potential differential responses to dietary intervention.",[25],[674,25,675,676,677],"Psychobiotic diet","Fermented foods","Gut-Brain Axis","Dietary fibre","2026-02-09",{"date":680,"type":36},"2026-02-12",{"date":682,"type":21},"2026-02",{"date":684,"type":21},"2028-05",{"name":686,"class":128},"University College Cork",{"id":688,"slug":689,"hasResults":12,"nctId":690,"briefTitle":691,"officialTitle":692,"acronym":4,"eligibilityCriteria":693,"healthyVolunteers":12,"sex":16,"minAge":249,"maxAge":694,"enrollmentInfo":695,"targetDuration":4,"studyType":68,"phases":697,"briefSummary":698,"conditions":699,"keywords":4,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":700,"startDateStruct":702,"completionDateStruct":704,"leadSponsor":706,"locationsCount":44},"100402923","fidgeting-and-attentional-and-emotional-regulation-in-adhd-100402923","NCT04526600","Fidgeting and Attentional and Emotional Regulation in ADHD","Can Fidgeting Lead to Enhanced Attention and Emotional Regulation in ADHD?","Inclusion Criteria:\n\n* ADHD\n* History of fidgeting\n\nExclusion Criteria:\n\n* Currently taking psychoactive medication, with the exception of stimulant medication for ADHD or medication that can affect heart rate;\n* Presence of significant depression or psychotic disorders, autism, visual or hearing impairment or any other disorder that may interfere with task performance; and IQ below 85","30 Years",{"count":696,"type":21},109,[108],"This project will study how fidgeting relates to cognitive and emotional functioning in adults with attention-deficit\u002Fhyperactivity disorder (ADHD). It will determine, in a laboratory setting, whether movement and access to a \"fidget device\" providing sensory and motor stimulation can improve cognitive and emotional regulation (including on physiological measures) in adult ADHD. The investigators will also acquire pilot data for machine learning analyses to be used in future, large scale studies to identify gestures and touch characteristics associated with improved cognitive and emotional regulation to see if the data can predict and subsequently develop recommendations to improve performance and emotional control in natural settings (e.g., home, office, college classroom) for adult ADHD.",[25],{"date":701,"type":36},"2026-02-11",{"date":703,"type":36},"2022-03-21",{"date":705,"type":21},"2026-06-01",{"name":707,"class":128},"University of California, Davis",{"id":709,"slug":710,"hasResults":12,"nctId":711,"briefTitle":712,"officialTitle":713,"acronym":714,"eligibilityCriteria":715,"healthyVolunteers":12,"sex":16,"minAge":249,"maxAge":594,"enrollmentInfo":716,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":718,"conditions":719,"keywords":4,"overallStatus":260,"whyStopped":4,"lastUpdateSubmitDate":723,"lastUpdatePostDateStruct":724,"startDateStruct":726,"completionDateStruct":728,"leadSponsor":730,"locationsCount":44},"100622888","evaluate-the-effects-of-long-term-use-of-psychotropic-medications-on-eye-movement-patterns-with-the-gaize-device-100622888","NCT07389473","Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device","An Observational Study to Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device","Rx Meds Gaize","Inclusion Criteria:\n\n* Adults aged between 18 and 65, having given written informed consent to participate in the research trial.\n* Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.\n* Normal or corrected to normal vision using either glasses or contact lenses, or surgery.\n\nExclusion Criteria:\n\n* Enrolled in, or participated in another clinical trial within 30 days before the study\n* Having a prosthetic eye, missing eye, or wearer of an eye patch LASIK or other eye surgery within the prior 21 days.\n* Had your eyes dilated by a medical doctor in the previous 24 hours.\n* Photosensitive epilepsy\n* Diagnosed with clinical blindness\n* Medical Conditions: Participants with medical conditions or medications that could significantly affect cognitive and motor functions are excluded. Participants with conditions such as Glaucoma, macular degeneration, cataracts, lazy eye (amblyopia), or optic neuritis, or genetic anisocoria (unequal pupil size) will be excluded.\n* Current or past head inject\u002F traumatic brain injury (TBI)\n* Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with psychiatric medications.\n* History of Severe Motion Sickness: Participants with a history of severe motion sickness in VR environments may be excluded, as they may not tolerate the VR headset well.\n* Potential participants who are unable to provide consent for the study.",{"count":717,"type":21},50,"The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled virtual environment.",[25,111,720,721,722],"Mood Disorders","Anxiety Disorder Generalized","Bipolar Disorder (BPD)","2026-02-04",{"date":725,"type":36},"2026-02-05",{"date":727,"type":36},"2024-04-17",{"date":729,"type":21},"2028-08",{"name":731,"class":94},"Gaize"]